Aline de Cristo Soares Alves
Overview
Explore the profile of Aline de Cristo Soares Alves including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
112
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Cristo Soares Alves A, Dallemole D, Medeiro Ciocheta T, Weber A, da Silva Gundel S, Visioli F, et al.
Int J Pharm X
. 2024 Jan;
6:100193.
PMID: 38204452
Nanoencapsulation of chemotherapeutics, including doxorubicin, can endow the formulations with unique properties, such as a decrease in adverse effects and toxicity. The chicken embryo model is an alternative and well-accepted...
2.
Broering M, de Castro Leao M, da Rocha G, Scharf P, Xavier L, de Cristo Soares Alves A, et al.
Eur J Pharm Biopharm
. 2022 Nov;
181:49-59.
PMID: 36334840
Annexin A1 (AnxA1), a 37KDa protein, is secreted by inflammatory and epithelial cells and displays anti-inflammatory and wound healing activities in intestinal bowel diseases. Herein, we aimed to functionalize recombinant...
3.
Bruinsmann F, de Cristo Soares Alves A, de Fraga Dias A, Lopes Silva L, Visioli F, Pohlmann A, et al.
Int J Pharm
. 2022 Feb;
616:121563.
PMID: 35151819
Glioblastoma is the most common and lethal malignant brain tumor. Despite simvastatin (SVT) showing potential anticancer properties, its antitumoral effect against glioblastoma appears limited when the conventional oral administration route...
4.
de Cristo Soares Alves A, Lavayen V, de Fraga Dias A, Bruinsmann F, Scholl J, Ce R, et al.
Nanomedicine (Lond)
. 2021 Jul;
16(20):1775-1790.
PMID: 34313137
To evaluate the antitumor efficacy of bevacizumab-functionalized nanocapsules in a rat glioblastoma model after the pretreatment with nanocapsules functionalized with a peptide-specific to the epidermal growth factor receptor variant III....
5.
de Cristo Soares Alves A, Bruinsmann F, Guterres S, Pohlmann A
Molecules
. 2021 Jul;
26(14).
PMID: 34299401
Bevacizumab (BCZ) is a recombinant humanized monoclonal antibody against the vascular endothelial growth factor, which is involved in the angiogenesis process. Pathologic angiogenesis is observed in several diseases including ophthalmic...
6.
Dallemole D, Terroso T, de Cristo Soares Alves A, Scholl J, Onzi G, Ce R, et al.
Pharmaceutics
. 2021 Jul;
13(6).
PMID: 34208088
Glioblastoma (GB) is a histological and genetically heterogeneous brain tumor that is highly proliferative and vascularized. The prognosis is poor with currently available treatment. In this study, we evaluated the...
7.
Frota Cavalcante M, Adorne M, Turato W, Kemmerer M, Uchiyama M, Asbahr A, et al.
Front Med (Lausanne)
. 2021 May;
8:652137.
PMID: 33959626
Atherosclerosis can be originated from the accumulation of modified cholesterol-rich lipoproteins in the arterial wall. The electronegative LDL, LDL(-), plays an important role in the pathogenesis of atherosclerosis once this...
8.
Ce R, Lavayen V, Couto G, De Marchi J, Pacheco B, Natividade L, et al.
Pharm Res
. 2021 Feb;
38(2):301-317.
PMID: 33608808
Purpose: Folic acid-doxorubicin-double-functionalized-lipid-core nanocapsules (LNC-CS--Zn-DOX-FA) were prepared, characterized, and evaluated in vitro against ovarian and bladder cancer cell lines (OVCAR-3 and T24). Methods: LNC-CS--Zn-DOX-FA was prepared by self-assembly and interfacial...
9.
Docosahexaenoic acid nanoencapsulated with anti-PECAM-1 as co-therapy for atherosclerosis regression
de Castro Leao M, Pohlmann A, de Cristo Soares Alves A, Farsky S, Uchiyama M, Araki K, et al.
Eur J Pharm Biopharm
. 2020 Dec;
159:99-107.
PMID: 33358940
Atherosclerosis is a non-resolving inflammatory condition that underlies major cardiovascular diseases.Recent clinical trial using an anti-inflammatory drug has showna reduction of cardiovascular mortality, but increased the susceptibility to infections. For...
10.
Bruinsmann F, Buss J, Souto G, Schultze E, de Cristo Soares Alves A, Seixas F, et al.
AAPS PharmSciTech
. 2020 Aug;
21(6):229.
PMID: 32778976
Lung cancer is the most frequent type of cancer and the leading cause of cancer-related mortality worldwide. This study aimed to develop erlotinib (ELB)-loaded poly(ε-caprolactone) nanocapsules (NC) and evaluated their...